Liquidia (LQDA) Research & Development (2020 - 2026)
Liquidia's (LQDA) quarterly Research & Development came in at $12.6 million in Q1 2026, up 80.46% year-on-year from $7.0 million in Q1 2025, and down 25.8% quarter-over-quarter from $16.9 million in Q4 2025.
Liquidia (LQDA) Research & Development (2020 - 2026) Analysis & Trends
Liquidia's Research & Development history runs 7 years deep, the most recent figure standing at $12.6 million for Q1 2026.
- On a quarterly basis, Research & Development rose 80.46% year-over-year to $12.6 million in Q1 2026; TTM through Mar 2026 was $44.9 million, a 0.29% change from a year earlier, with the FY2025 full-year figure at $39.3 million, down 17.9% from the prior year.
- Research & Development eased to $12.6 million in Q1 2026 per LQDA's latest filing, from $16.9 million in the prior quarter.
- Across five years, Research & Development topped out at $17.7 million in Q2 2023 and bottomed at $4.5 million in Q3 2022.
- The 5-year median for Research & Development is $9.3 million (2025), against an average of $9.6 million.
- Across the five-year window, Research & Development surged 239.05% in 2023 and sank 46.76% in 2024, its largest moves.
- Year by year, Research & Development stood at $5.0 million in 2022, then soared by 157.82% to $12.8 million in 2023, then gained by 28.42% to $16.5 million in 2024, then gained by 2.84% to $16.9 million in 2025, then retreated by 25.8% to $12.6 million in 2026.
- Per Business Quant, the three latest LQDA Research & Development figures stand at $12.6 million (Q1 2026), $16.9 million (Q4 2025), and $9.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 12.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.57 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Sep 30, 2025 | 9.35 Mn |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 16.48 Mn |
| Sep 30, 2024 | 11.89 Mn |
| Jun 30, 2024 | 9.42 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 12.83 Mn |
| Sep 30, 2023 | 7.44 Mn |
| Jun 30, 2023 | 17.70 Mn |
| Mar 31, 2023 | 5.28 Mn |
| Dec 31, 2022 | 4.98 Mn |
| Sep 30, 2022 | 4.51 Mn |
| Jun 30, 2022 | 5.22 Mn |
| Mar 31, 2022 | 4.73 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 4.49 Mn |
| Jun 30, 2021 | 4.60 Mn |